TY - JOUR
T1 - Optimising endocrine approaches for the chemoprevention of breast cancer. Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial
AU - Jordan, V. Craig
N1 - Funding Information:
Dr. Jordan is supported by the Department of Defence Breast Programme under award number BC050277 Centre of Excellence (views and opinions of, and endorsements by, the author(s) do not reflect those of the US Army or the Department of Defence), SPORE in Breast Cancer CA 89018, R01 GM067156, FCCC Core Grant NIH P30 CA006927, the Avon Foundation and the Weg Fund of the Fox Chase Cancer Centre. I would like to thank Professor Alan Roberts and Dr. Stan Dobrzanski of the Bradford Teaching Hospitals NHS Foundation Trust for their invaluable assistance with UK drug pricing.
PY - 2006/11
Y1 - 2006/11
N2 - The completion of the Study of Tamoxifen and Raloxifene (STAR) [Vogel VG, Costantino JP, Wickerham DL, et al. The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. JAMA 2006;295:2727-2741.] and the ongoing studies with aromatase inhibitors [Goss PE. Breast cancer prevention-clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 2003;86(3-5):487-93.] to assess their worth for the chemoprevention of breast cancer, creates an opportunity to consider the realistic future for chemoprevention as an option for women's healthcare and to identify strategies for future progress in an era of targeted therapeutics, managed healthcare and soaring costs.
AB - The completion of the Study of Tamoxifen and Raloxifene (STAR) [Vogel VG, Costantino JP, Wickerham DL, et al. The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial. JAMA 2006;295:2727-2741.] and the ongoing studies with aromatase inhibitors [Goss PE. Breast cancer prevention-clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 2003;86(3-5):487-93.] to assess their worth for the chemoprevention of breast cancer, creates an opportunity to consider the realistic future for chemoprevention as an option for women's healthcare and to identify strategies for future progress in an era of targeted therapeutics, managed healthcare and soaring costs.
KW - STAR
UR - http://www.scopus.com/inward/record.url?scp=33750508737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750508737&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2006.09.012
DO - 10.1016/j.ejca.2006.09.012
M3 - Article
C2 - 17064889
AN - SCOPUS:33750508737
SN - 0959-8049
VL - 42
SP - 2909
EP - 2913
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 17
ER -